Evidence map›Paper›PMID 40819841›Full record

ReviewJournal of obesity & metabolic syndrome2025

2024 Clinical Practice Guidelines for the Diagnosis and Pharmacologic Treatment of Overweight and Obesity by the Korean Society for the Study of Obesity.

Jae Hyun Bae, Ji-Hee Haam, Eonju Jeon, Seo Young Kang, SuJin Song, Cheol-Young Park, Hyuktae Kwon, Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)

Abstract readReview
In one paragraph

Review in Journal of obesity & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jae Hyun BaeDivision of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Ji-Hee HaamDepartment of Family Medicine, Well-Bon Clinic, Hwaseong, Korea.
Eonju JeonDivision of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Seo Young KangDepartment of Family Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Korea.
SuJin SongDepartment of Food and Nutrition, Hannam University, Daejeon, Korea.
Cheol-Young ParkDepartment of Internal Medicine, Kangbuk Samsung Hospital, Seoul, Korea.ORCID 0000-0002-9415-9965
Hyuktae KwonDepartment of Family Medicine, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-0312-3650
Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Korean Society for the Study of Obesity has published the 9th edition of its Clinical Practice Guidelines to provide updated, evidence-based recommendations for the management of overweight and obesity. Developed through a structured process of systematic literature review and expert consensus, these guidelines incorporate recent clinical evidence for obesity management. Key clinical questions were formulated using the Population, Intervention, Comparison, and Outcome framework and addressed through comprehensive evaluations of randomized controlled trials, cohort studies, systematic reviews, and existing guidelines. Major updates include the inclusion of the concept of clinical obesity, defined as excessive adiposity with tissue and organ dysfunction. The revised guidelines expand recommendations for pharmacologic treatments and introduce a new section on health functional foods. Emphasis is placed on early assessment of treatment response and individualized therapeutic adjustments to improve long-term outcomes. The guidelines also highlight the importance of recognizing obesity-related health conditions and ensuring equitable access to care. They promote shared decision-making and ethical prescribing practices to support a person-centered approach. All recommendations are evaluated using the Grading of Recommendations Assessment, Development and Evaluation system, which reflects the strength of evidence and the balance of expected benefits and harms. These updates are intended to assist healthcare providers in delivering personalized, evidence-informed care and underscore the evolving role of pharmacotherapy within risk-based obesity management strategies.

Indexed as

Anti-obesity agentsComorbidityObesityObesity managementOverweightPractice guideline

Identifiers

PMID40819841
PMCPMC12583794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.